Showing 841-850 of 19239 results for "".
LH vs hCG: Formulations and Physiological Differences
https://reachmd.com/programs/global-womens-health-academy/lh-vs-hcg-formulations-and-physiological-differences/9556/Join Dr. Sandro Esteves in this excerpt of his live presentation entitled LH vs. hCG: Formulations and Physiological Differences, delivered during EXCEMED’s First World Conference on Luteinizing Hormone in ART: Landing in Latin America held in Mexico City, Mexico on 7 April 2017. This presentation iImmunotherapy for Management of Refractory and Super-Refractory Status Epilepticus
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/immunotherapy-for-management-of-refractory-and-super-refractory-status-epilepticus/39948/This review explores the role of neuroinflammation in refractory and super-refractory status epilepticus, as well as the role of therapeutic immunomodulation in their management.Selecting the Right Neuromodulator
https://modernaesthetics.com/ma-issues-index/march-april-2026-issue/selecting-the-right-neuromodulator/56635/Subtle differences in botulinum toxin formulations and technique shape individualized aesthetic outcomesClosing the Gap to Care: Assessing CAD and Improving Patient Outcomes with Revascularization
https://reachmd.com/programs/cme/closing-the-gap-to-care-assessing-cad-and-improving-patient-outcomes-with-revascularization/14855/Are we really doing our best to assess CAD in our patients? Experts discuss ways to close gaps in care and improve patient outcomes.Epilepsy Essentials: Novel Interictal Biomarkers for Delineating the Epileptogenic Zone in Children With Drug-Resistant Epilepsy
https://reachmd.com/programs/practical-neurology-focus-on-epilepsy-seizures/epilepsy-essentials-novel-interictal-biomarkers-for-delineating-the-epileptogenic-zone-in-children-with-drug-resistant-epilepsy/32147/Novel interictal biomarkers of epilepsy are able to identify the epileptogenic zone with precision and predict surgical outcome in children with drug-resistant epilepsy.On the Frontline: Empowering IO Therapies for Patients with HER2-Negative G/GEJC
https://reachmd.com/programs/project-oncology/io-therapies-for-patients-with-her2-negative-ggejc/35513/For patients who are diagnosed with metastatic gastric cancer, the five-year overall survival rate is roughly seven percent, underscoring the need for additional treatment options.1 Fortunately, there has been advancement in gastric cancer care, including the FDA approval of tislelizumab plus platinDr. Dean Ornish, President of the Preventive Medicine Research Institute
https://reachmd.com/programs/conversations-on-health-care/dr-dean-ornish-president-preventive-medicine-research-institute/7939/This week, hosts Mark Masselli and Margaret Flinter speak with Dr. Dean Ornish, Founder and President of the Preventive Medicine Research Institute. He analyzes the new USDA nutritional guidelines and discusses the mounting empirical evidence linking sound nutrition and integrative medicine to the pNon-Stimulant Options for ADHD Patients
https://reachmd.com/programs/focus-on-neurology-and-psychiatry/non-stimulant-options-for-adhd-patients/4383/Although stimulant medications are often used to treat ADHD patients, there are patients for whom non-stimulants might also be a viable option. What are the advantages to each type of medication? Dr. Richard Rubin, clinical associate professor at the University of Vermont College of Medicine and adjAesthetic Laser Innovators Discuss What Is Next
https://reachmd.com/programs/modern-aesthetics-focus-on-energy-based-devices/aesthetic-laser-innovators-discuss-what-is-next/56627/A roundtable discussion with Jill S. Waibel, MD, FACS, FAAD; R. Rox Anderson, MD, FAAD; Roy Geronemus, MD; and E. Victor Ross, MD, FAADThe Genetics of Migraine: Advancing Diagnosis and Personalizing Treatment
https://reachmd.com/programs/frontlines-migraine/the-genetics-of-migraine-advancing-diagnosis-and-personalizing-treatment/36156/Decades of research have transformed our understanding of migraine genetics, from rare monogenic types to complex polygenic forms. Mr. Ryan Quigley is joined by Dr. Lyn Griffiths to explore polygenic risk scores, emerging diagnostic tools, and the promise of personalized medicine in migraine